|
Match
|
Document |
Document Title |
|
|
7618633 |
Antibodies that bind CD40 and methods of treating cancer and enhancing immune responses
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also...
|
|
|
7615219 |
Inhibition of PACAP signalling for the prevention and treatment of thrombocytopenia
The present invention discloses the use of inhibitors and/or antagonists of PACAP signalling for the manufacture of a medicament for the prevention or treatment of decreased blood platelet numbers...
|
|
|
7611707 |
Glycoprotein VI antibodies and methods thereof
The present invention describes antibodies generated against platelet membrane glycoprotein VI-(GPVI), methods of producing the anti-GPVI antibodies, and the use of these antibodies as research and...
|
|
|
7611708 |
Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies
Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment...
|
|
|
7604800 |
Anti-PSGL-1 antibodies
Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of...
|
|
|
7592006 |
Composition comprising the LO-CD2a antibody
The present invention relates to a LO-CD2a antibody and methods of using such antibodies or molecules that bind to the same epitope (or a portion thereof) to prevent and inhibit an immune response...
|
|
|
7592007 |
Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA-4 specific antibodies
Isolated ligands which bind a molecule expressed on the surface of T cells and induce antigen specific apoptosis in activated T cells are disclosed. Preferably, the T cell surface molecule is CTLA4...
|
|
|
7563445 |
CD40 binding molecules and CTL peptides for treating tumors
Disclosed is a method and composition for treating tumors or infectious diseases, wherein the composition includes CD40 binding molecules together with CTL-activating peptides, e.g., tumor...
|
|
|
7563442 |
Antibodies to CD40 and methods of treating cancer and enhancing immune responses
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also...
|
|
|
7563443 |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential...
|
|
|
7563441 |
Anti-P-selectin antibodies
This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind...
|
|
|
RE40811 |
Peripheralization of hematopoietic stem cells
The invention relates to in vivo peripheralization of CD34 + cells by administering anti-VLA-4 antibodies or anti-VCAM-1 antibodies.
|
|
|
7547438 |
CD40-binding activating antibodies
Disclosed are agonist anti-CD40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells (“APCs”), enhance...
|
|
|
7537763 |
Anti-CD40 monoclonal antibody
An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40.
|
|
|
7531175 |
Methods for modulation of immune responses using humanized immunoglobulins reactive with B7-1 molecules
The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The...
|
|
|
7510712 |
Methods of treating rheumatoid arthritis with 7C10 and 16C10 CD80-specific antibodies
The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and...
|
|
|
7510713 |
Methods of inducing immunosuppression by administering 7C10 and 16C10 CD80-specific antibodies
The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and...
|
|
|
7510711 |
Methods for the treatment of cancer using anti-CD40 antibodies
The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the...
|
|
|
7501496 |
Anti-OX40L antibodies
This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor...
|
|
|
7501124 |
Methods of inducing T-cell non-responsiveness with anti-gp39 24-31 antibodies
Methods for inducing T cell tolerance to a tissue or organ graft in a transplant recipeint are disclosed. The methods involve administering to a subject: 1) an allogeneic or xenogeneic cell which...
|
|
|
7498032 |
Methods for treating immune disorders or cancer with anti-CD40 antibodies
The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the...
|
|
|
7491393 |
Methods of inhibiting IL-2 production by T cells by administering 7C10 and 16C10 CD80-specific antibodies
The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and...
|
|
|
7482003 |
Treatment for asthma with α4-specific antibodies
The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific...
|
|
|
7476385 |
Methods of inhibiting IgE responses to thymus-dependent antigens with the anti-gp39 antibody MR1
Methods of suppressing a humoral immune response to a thymus-dependent (TD) antigen are disclosed. The methods involve administering to a subject a TD antigen with an antagonist of a molecule which...
|
|
|
7465464 |
Populations of cells that express flk-2 receptors
Isolated mammalian nucleic acid molecules encoding receptor protein tyrosine kinases expressed in primitive hematopoietic cells and not expressed in mature hematopoietic cells are provided. Also...
|
|
|
7462352 |
Methods of treatng B-cell diseases using humanized anti-CD19 antibodies
The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies,...
|
|
|
7445780 |
Antagonistic anti-CD40 antibodies
Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment...
|
|
|
7445798 |
Populations of cells that express FLK-1 receptors
Isolated mammalian nucleic acid molecules encoding receptor protein tyrosine kinases expressed in primitive hematopoietic cells and not expressed in mature hematopoietic cells are provided. Also...
|
|
|
7445781 |
Anti-CD40CR MR1 antibody
The present invention relates to a counter-receptor, termed CD40CR, for the CD40 B-cell antigen, and to soluble ligands for this receptor, including fusion molecules comprising at least a portion...
|
|
|
7429647 |
Polypeptides capable of forming antigen binding structures with specificity for the Rhesus D antigens, the DNA encoding them and the process for their preparation and use
Polypeptides capable of forming antigen binding structures specific for Rhesus D antigens include the sequences indicated in the FIGS. 1 a to 16 b . The obtained polypeptides, being Fab...
|
|
|
7422739 |
Anti-CD20 antibodies
Disclosed are chimeric, immunologically active, isolated, and radiolabeled antibodies directed against the CD20 antigen. The antibodies are useful for treating and diagnosing B cell disorders.
|
|
|
7422745 |
Methods of treating cancer with vαβ3-specific antibodies
The invention provides a Vitaxin antibody and a LM609 grafted antibody exhibiting selective binding affinity α v β 3 . The Vitaxin antibody consists of at least one Vitaxin heavy chain...
|
|
|
7422744 |
Methods of treating cancer with alphavbeta3-specific antibodies
The invention provides a Vitaxin antibody and a LM609 grafted antibody exhibiting selective binding affinity to α v β 3 . The Vitaxin antibody consists of at least one Vitaxin heavy chain...
|
|
|
7393529 |
Methods and compositions for inhibiting binding of IgE to a high affinity receptor
The invention provides methods and compositions for inhibiting binding of IgE to a high affinity receptor. The methods and compositions are useful in the treatment of allergic diseases and allergy...
|
|
|
7371382 |
Methods of inhibiting αvβ3-mediated binding with αvβ3-specific antibodies
The invention provides enhanced LM609 grafted antibodies exhibiting selective binding affinity to α V β 3 , or a functional fragment thereof. The invention also provides nucleic acid molecules...
|
|
|
7361344 |
Co-administration of a thrombolytic and an-anti-CD18 antibody in stroke
A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective...
|
|
|
7354577 |
Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) and uses thereof
A novel protein Common Lymphatic Endothelial and Vascular Endothelial Receptor-1 (CLEVER-1) is described. CLEVER-1 mediates leukocyte and malignant cell binding to vascular and lymphoid endothelial...
|
|
|
7338660 |
Methods of treating cancer and enhancing immune responses with antibodies that bind CD40
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also...
|
|
|
7323171 |
Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction
Methods of using inhibitors of the CD2/LFA-3 interaction in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in...
|
|
|
7323170 |
Anti-CD80 antibodies
The present invention relates to the identification of macaque antibodies to human B7.1 and B7.2 by screening of phage display libraries or monkey heterohybridomas obtained using B lymphocytes from...
|
|
|
7309489 |
Mouse CD40 ligand-specific antibodies and hybridomas
There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human...
|
|
|
7288251 |
Antibodies to CD40
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also...
|
|
|
7288252 |
Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies
Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment...
|
|
|
7259247 |
Anti-human T-cell costimulating polypeptide monoclonal antibodies
A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against said 8F4 molecule and hybridoma cells which produce the...
|
|
|
7192585 |
CD80 specific antibodies
The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and...
|
|
|
7175847 |
Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and...
|
|
|
7172759 |
Induction of cytotoxic T lymphocyte responses using anti-CD40 antibodies
Disclosed are methods of inducing maturation of antigen presenting cells and cytotoxic T lymphocyte responses utilizing agonist anti-CD40 antibodies that do not block the binding of CD40L to CD40.
|
|
|
7169389 |
Human CD154 binding molecules and treatment methods
A CD154 binding molecule, in particular an antibody to human CD154, especially a human antibody to human CD154 is provided, wherein the CDRs of the heavy chain and light chain have amino acid...
|
|
|
7157086 |
Treatment for inflammatory bowel disease with α4-specific antibodies
The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific...
|
|
|
7153508 |
Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and...
|